Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

NCT07175441 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable Hepatocellular Carcinoma

Interventions

DRUG: RBS2418
DRUG: STRIDE (durvalumab + tremelimumab)

Sponsor

Riboscience, LLC.